Coulter Partners Recruits CEO for Nitinotes

October 22, 2024 – Life sciences recruiting specialist Coulter Partners has assisted in the recruitment of Lloyd Diamond as the new CEO of Nitinotes Surgical in Caesarea, Israel. He succeeds Raz Bar-On, who will continue as  general manager. “We are thrilled to welcome Lloyd to lead Nitinotes into its next chapter of innovation and growth,” said John Barr, chairman of the board. “Building upon the foundation established and the exceptional achievements attained, his extensive experience in medical technologies positions him as an outstanding leader to advance our future initiatives.”

“Lloyd’s appointment concludes a rigorous executive search process that MTIP initiated in collaboration with Coulter Partners,” Mr. Barr said. “We express our deep gratitude to Coulter Partners for their exceptional support. Their expert guidance was invaluable in identifying the ideal leader for Nitinotes. Their deep understanding of our specific needs and extensive network within the market were instrumental in delivering a successful outcome. Given the complexity of this role, finding the right candidate was a challenging task, but Coulter Partners’ professionalism and dedication ensured we found the perfect match.”

Mr. Diamond is a seasoned life sciences executive with over 30 years of experience in the medtech and biotech sectors. He has led fundraising, M&A, and IPO transactions for startups, high-growth companies, and turnarounds. Mr. Diamond has a track record in driving the commercialization of disruptive medical technologies across various clinical segments, including orthopedics, ophthalmology, and urology, in global markets. He has experience in managing sales organizations, negotiating agreements with key healthcare institutions, and securing reimbursement policies. Prior to joining Nitinotes, Mr. Diamond served as CEO at Pixium Vision, where he advanced bionic vision systems.

“I am honored to join Nitinotes at this pivotal time,” said Mr. Diamond. “With obesity rates rising worldwide and over 1 billion people affected, EndoZip provides a critical solution to a significant global health challenge. I look forward to working with the talented team to bring this solution to more patients and healthcare providers worldwide.”

Related: Coulter Partners Recruits CEO for ArcticZymes Technologies

Nitinotes, backed by MTIP, is a pioneer in medical technology and a leader in innovative obesity treatment. The company developed EndoZip, a minimally invasive, fully automated endoscopic suturing system aimed at treating obesity. MTIP first invested in Nitinotes in March 2018 and has continued to support the company ever since. The Swiss-based growth equity firm played a crucial role in introducing Nitinotes to Coulter Partners, enabling the search for top-tier leadership talent.

Life Sciences Specialists

Coulter Partners is a board- and senior-level global executive search specialist focused exclusively on life sciences. The firm works closely with those at the cutting edge of innovation in the industry to understand their challenges. With an extensive global network and expertise gained over 25 years in the sector, Coulter Partners is a trusted leadership adviser in the pharmaceuticals, biotechnology, medical technology, diagnostics, health-tech, CRO, and services sectors. The firm also works closely with the global investor community, hiring for their own teams as well as building the boards and executive leadership teams of their portfolio companies. Coulter Partners’ team of 95 completes over 260 assignments a year working from 14 offices across the U.K., EMEA, the U.S., and APAC.


Coulter Partners Forms Alliance with the Institute of Neurodiversity

Coulter Partners has formed a partnership with the Institute of Neurodiversity (ION). As a global neurodiversity changemaking organization and community, ION looks to foster awareness, acceptance, and appreciation of neurodiversity. They work with organizations, governments, the third sector, educators, and policymakers to raise awareness and advocate for policies that support neurominority inclusion. “We believe that our partnership with ION will enhance our understanding and deepen our knowledge,” said Bianca Coulter, CEO of Coulter Partners. “This will enable us to better support neurominorities and advocate change, as well as have measurable impact on good governance and transparency.”


Bianca Coulter founded Coulter Partners in 2003 and has 25 years’ experience of board and C-level global search, building the leadership teams of early stage, mid-cap, and global multinationals in over 20 countries. Through appointing leadership, Ms. Coulter channels her judgment and expertise to impact patient benefit and assist those at the cutting edge of life science to achieve their goals.

Coulter Partners recently placed Matthew Sassone as the new CEO of Tristel plc, a manufacturer of infection prevention products. He replaced Paul Swinney, the company’s founder and CEO of 30 years, who announced his plans to retire during 2023. Mr. Swinney will remain with the company for a suitable period to allow for a successful transition of leadership. “Matt’s appointment follows the conclusion of a competitive selection program and I would like to extend our sincere thanks to Coulter Partners for their invaluable support throughout this executive search process,” said Bruno Holthof, chair of Tristel. “Finding the right leader for Tristel was a complex and challenging task, but their professionalism, dedication, and expertise were instrumental in identifying Matt Sassone as the ideal candidate. We are grateful for their partnership.”

Related: Coulter Partners Recruits Chief Development Officer for CellCentric

Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor  – Hunt Scanlon Media

Share This Article

RECOMMENDED ARTICLES

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments